Mark Ricigliano, DO
Family Medicine · Pennsauken, NJNPI 1366482630
Payments from drug & device makers
Across 486 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$547
- Lilly USA, LLC$515
- Amarin Pharma, Inc.$457
- Boehringer Ingelheim$453
- AbbVie$422
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,584100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,057 |
| Novo Nordisk | 47 | $547 |
| Lilly USA, LLC | 33 | $515 |
| Amarin Pharma, Inc. | 36 | $457 |
| Boehringer Ingelheim | 34 | $453 |
| AbbVie | 43 | $422 |
| Sanofi-aventis U.S. LLC | 29 | $385 |
| Pfizer | 26 | $335 |
| GSK | 23 | $296 |
| Kowa Pharmaceuticals America, Inc. | 17 | $246 |
| Johnson & Johnson | 17 | $239 |
| Merck | 17 | $218 |
| Amgen | 13 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $149 |
| Bayer | 10 | $139 |
| Astellas Pharma US Inc | 8 | $111 |
| Abbott | 6 | $98 |
| Almatica Pharma LLC | 7 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $95 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Novartis | 3 | $54 |
| Eisai Inc. | 3 | $51 |
| Exact Sciences | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 4 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Hikma Pharmaceuticals USA | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Linus Health, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$6,614 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $85,853 |
| FarxigaDapagliflozin Propanediol | 70 | $73,074 |
| JardianceEmpagliflozin | 40 | $64,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $54,846 |
| OzempicSemaglutide | 28 | $42,807 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $35,860 |
| MounjaroTirzepatide | 24 | $30,367 |
| RybelsusSemaglutide | 12 | $30,236 |
| MyrbetriqMirabegron | 16 | $20,451 |
| XareltoRivaroxaban | 13 | $20,086 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,723 |
| Atorvastatin Calcium | 590 | $6,551 |
| Rosuvastatin Calcium | 297 | $6,090 |
| Arnuity ElliptaFluticasone Furoate | 12 | $5,628 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 134 | $4,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $335 | $85,85391 claims |
| AstraZenecaFarxiga | $1,057 | $73,07470 claims |
| Novo NordiskOzempic, Rybelsus | $547 | $73,04240 claims |
| Boehringer IngelheimJardiance | $453 | $64,60140 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $296 | $60,47453 claims |
| MerckJanumet Xr | $218 | $35,86028 claims |
| Lilly USA, LLCMounjaro | $515 | $30,36724 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $20,45116 claims |
| Johnson & JohnsonXarelto | $239 | $20,08613 claims |
| AbbVieSynthroid | $422 | $1,59825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Pennsauken
- Steven SantangeloPennsauken$14K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.